Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013

0
410
Spread the love

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today reported financial results for the three months and year ended December 31, 2013, and provided an update of recent corporate developments. …read more    

Comments are closed.

More News